

2-Arylamino-4-Amino-5-Aroylthiazoles. “One-Pot” Synthesis and Biological Evaluation of a New Class of Inhibitors of Tubulin Polymerization

Romeo Romagnoli,^{*,†} Pier Giovanni Baraldi,^{*,†} Maria Dora Carrion,[†] Olga Cruz-Lopez,[†] Carlota Lopez Cara,[†] Giuseppe Basso,[‡] Giampietro Viola,[‡] Mohammed Khedr,^{||} Jan Balzarini,[§] Siavosh Mahboobi,[⊥] Andreas Sellmer,[⊥] Andrea Brancale,^{||} and Ernest Hamel[#]

[†]Dipartimento di Scienze Farmaceutiche, Università di Ferrara, 44100 Ferrara, Italy, [‡]Dipartimento di Pediatria, Laboratorio di Oncoematologia, Università di Padova, 35131 Padova, Italy, [§]Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Minderbroedersstraat 10, B-3000 Leuven, Belgium, ^{||}The Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, U.K., [⊥]Faculty of Chemistry and Pharmacy, University of Regensburg, D-93040 Regensburg, Germany, and [#]Toxicology and Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland 21702

Received February 10, 2009

The essential role of microtubules in mitosis makes them a major target of compounds useful for cancer therapy. In our search for potent antitumor agents, a novel series of 2-anilino-4-amino-5-arylothiazoles was synthesized and evaluated for antiproliferative activity, inhibition of tubulin polymerization, and cell cycle effects. SAR was elucidated with various substitutions on the phenylamino and aroyl moiety at the 2- and 5-positions, respectively, of the 4-aminothiazole skeleton. Tumor cell exposure to several of these compounds led to the arrest of HeLa cells in the G2/M phase of the cell cycle and induction of apoptosis.

Introduction

There has been in recent years an intense effort in the discovery and development of novel small molecules, many of which are natural products, able to inhibit tubulin polymerization and have potential for the treatment of cancer.^{1,2} One of the most important antimetabolic agents is combretastatin A-4^a (CA-4, **1**; Chart 1). CA-4, isolated from the bark of the South African tree *Combretum caffrum*,³ is one of the well-known natural tubulin-binding molecules affecting microtubule dynamics by binding to the colchicine site.⁴ Replacement of the double bond of CA-4 with a carbonyl group furnished a synthetic benzophenone-type CA-4 analogue named phenstatin (**2a**), which demonstrated interesting efficacy in a variety of tumor models.⁵ The 2-aminobenzophenone derivative **2b** also strongly inhibited cancer cell growth and tubulin polymerization and caused mitotic arrest, as did **2a**.⁶

The classical bioisosteric equivalence between benzene and thiophene prompted us recently to synthesize a series of 2-(3',4',5'-trimethoxybenzoyl)-3-amino-5-phenyl thiophene derivatives with general formula **3**, in which the thiophene system replaced the benzene moiety in the 2-amino phenstatin analogue **2a**.⁷ The analysis of structures of 2-aminobenzophenone and 2-aryloxy-3-aminothiophenes (compounds **2b** and **3**, respectively) showed that the ortho relationship between the aroyl group and the 2-amino moiety plays an essential role in activity.

^aTo whom correspondence should be addressed. For R.R.: phone, 39-(0)532-455303; fax, 39-(0)532-455953; E-mail, rmr@unife.it. For P.G.B.: phone, 39-(0)532-455921; fax, 39-(0)532-455953; E-mail, baraldi@unife.it.

^bAbbreviations: CA-4, combretastatin A-4; EWG, electron-withdrawing group; ERG, electron-releasing group; SAR, structure–activity relationships; MeOH, methanol; MeONa, sodium methoxide.

Recently, investigators at Altana Pharma reported a series of 4-(imidazol-1-yl)thiazol-2-yl]phenylamine analogues with general structure **4**, active at submicromolar concentrations as antiproliferative agents against human colon adenocarcinoma (RKO p27) cells and that act as inhibitors of microtubule polymerization by interfering with the colchicine site of tubulin.⁸


As a part of our search for novel antimetabolic agents, these findings prompted us to synthesize a new series of 2-arylamino-4-amino-5-arylothiazole derivatives with general structure **5**, obtained by incorporating the 3-amino and 2-aryloxy moieties of compounds with general structure **3**, into the 4- and 5-positions, respectively, of the 2-aryloxythiazole nucleus of general formula **4**.⁹

While compounds **5a–f** were characterized by the unsubstituted 5-benzoylthiazole structure, we also prepared several derivatives in which the methoxy group was placed at the para (**5g–j**), meta (**5k–l**), or ortho (**5m–n**) position on the B-phenyl ring of the 5-benzoyl moiety. To analyze the effect of additional methoxy groups, we synthesized the 3',4'-dimethoxy benzoyl (**5o–p**) and 3',4',5'-trimethoxybenzoyl (**5q–v**) analogues. Finally, to validate whether EWG's at the para-position of the B-ring can replace the methoxy group of compound **5j** with retention of activity, we prepared the chloro (**5w**), bromo (**5x**), and nitro (**5y**) analogues. Once one, two, or three methoxy substituents were placed on the 5-benzoyl moiety, we explored SAR by examining various substitutions with electron-withdrawing (F, Cl, Br, and NO₂) and electron-releasing (Me and MeO) groups on the A-phenyl ring of the 2-anilino moiety.

Chemistry

The 2-anilino-4-amino-5-aryloxy thiazoles **5a–y** were synthesized in acceptable yield (35–55%) by a one-pot,

Chart 1. Inhibitors of Tubulin Polymerization




three-component reaction in MeOH of substituted phenyl isothiocyanates **6a–f** with α -bromoketones **7a–i** and cyanamide in a 1:1:1 ratio and in the presence of MeONa (in situ generated by methanol and sodium) as base (Scheme 1).¹⁰

Results and Discussion

The novel series of thiazole derivatives **5a–y** were evaluated for their antiproliferative activity against a panel of five tumor cell lines and compared with the reference compounds CA-4 (**1**) and **4a**, as shown in Table 1. Of all the tested compounds, derivative **5q** possessed the highest overall cytostatic potency, with IC_{50} values of 18, 23, 6, 9, and 14 nM against the L1210, FM3A, Molt4, CEM, and HeLa cell lines, respectively. It had comparable or slightly greater antiproliferative activity than CA-4 against three cell lines and was less potent in two lines. Comparing derivatives **5t** and **4a**, which shared a common 2-(*p*-methylanilino) thiazole moiety, **4a** was from 40- to 150-fold less active than **5t**.

In comparing the effect of ERG's or EWG's at the para-position of the A-phenyl ring, compounds with electron-donating methyl or methoxy groups were generally more cytostatic than those with the electron-withdrawing fluoro or chloro moieties. In six of the eight potent analogues (i.e., **5l**, **5n**, **5p–q**, and **5w–y**), there was a *para*-methoxy substitution on the A-phenyl ring, and the only inactive compound with this substituent was **5u**, while **5e** and **5j** had weak activity. The presence of the *para*-methoxy group in the A ring allowed a wide range of substituents in the B ring (*meta*- and *ortho*-methoxy groups in **5l** and **5n**, respectively; *para*-chloro, -bromo, and -nitro groups in **5w**, **5x**, and **5y**, respectively; and even a *meta*-, *para*-dimethoxy substitution in **5p**), but neither a bare B ring as in **5e**, a 4'-methoxy group as in **5j**, nor the 3',4',5'-trimethoxy substitution pattern of **5u** were tolerated. However, the 3',4',5'-trimethoxy substitution pattern was tolerated

Scheme 1^a

^a Reagents: (a) NH_2CN , Na, MeOH, rt.

Table 1. In Vitro Inhibitory Effects of Compounds **4a**, **5a–y** and CA-4 (**1**)

compd	IC ₅₀ ^a (nM)				
	L1210	FM3A	Molt4	CEM	HeLa
5a	8100 ± 200	8200 ± 100	7300 ± 1100	3900 ± 800	6100 ± 1600
5b	> 10000	> 10000	> 10000	> 10000	> 10000
5c	> 10000	> 10000	> 10000	> 10000	> 10000
5d	2800 ± 400	1500 ± 900	210 ± 130	370 ± 120	900 ± 260
5e	850 ± 170	730 ± 390	230 ± 140	300 ± 10	230 ± 50
5f	8200 ± 600	5000 ± 800	1500 ± 200	2900 ± 300	3200 ± 1100
5g	> 10000	> 10000	6900 ± 1900	9100 ± 5000	> 10000
5h	> 10000	> 10000	> 10000	> 10000	> 10000
5i	> 10000	> 10000	> 10000	> 10000	> 10000
5j	470 ± 58	630 ± 110	320 ± 70	1200 ± 110	330 ± 10
5k	7600 ± 2200	6200 ± 1900	1300 ± 100	2300 ± 200	1700 ± 0.0
5l	35 ± 14	50 ± 26	4.0 ± 2.3	9.9 ± 1.8	37 ± 12
5m	1100 ± 600	1100 ± 200	1300 ± 0.0	730 ± 490	1200 ± 100
5n	31 ± 11	52 ± 15	18 ± 2	17 ± 3	17 ± 0.0
5o	> 10000	> 10000	5500 ± 3700	6900 ± 1600	6000 ± 900
5p	38 ± 28	71 ± 26	37 ± 31	10 ± 2	52 ± 12
5q	18 ± 0.0	23 ± 10	6 ± 1.1	9.4 ± 3.6	14 ± 1
5r	900 ± 480	58 ± 100	280 ± 170	400 ± 20	440 ± 40
5s	420 ± 170	420 ± 10	110 ± 10	190 ± 70	180 ± 40
5t	31 ± 6.0	15 ± 3.0	21 ± 1.1	41 ± 3.5	86 ± 10
5u	1500 ± 1000	2200 ± 900	480 ± 150	1100 ± 0.0	560 ± 40
5v	2100 ± 300	2000 ± 300	530 ± 0.00	1300 ± 0.0	1000 ± 200
5w	84 ± 30	59 ± 37	13 ± 7	19 ± 6.9	83 ± 6
5x	110 ± 0.00	100 ± 0.00	16 ± 6	39 ± 11	79 ± 4
5y	280 ± 110	310 ± 160	29 ± 11	31 ± 12	350 ± 60
4a	1800 ± 71	1200 ± 0	510 ± 11	1500 ± 71	530 ± 64
CA-4	2.8 ± 1.1	42 ± 6.0	16 ± 1.4	12 ± 2.5	1.9 ± 1.6

^aIC₅₀ = compound concentration required to inhibit tumor cell proliferation by 50%.

with either no A ring substituent (the highly active **5q**) or the smaller A ring methyl substituent of **5t**.

The results also showed that, with the notable exception of **5q**, all compounds with no substituent in either ring A or ring B had minimal or reduced antiproliferative activity (**5a–g**, **5k**, **5m**, and **5o**). Again, with the exception of **5q**, the data showed that the ring B para-position is the least favorable for a methoxy group. However, para B ring EWG's are also associated with high antiproliferative activity when a *para*-methoxy-substituted A ring is also present (**5w–y**).

In the series of 3',4',5'-trimethoxybenzoyl thiazole derivatives **5q–v**, the unsubstituted 2-phenylamino derivative **5q** was the most active inhibitor of cell growth. Introduction of a fluorine (**5r**) or chlorine (**5s**) into the ortho-position of A-phenyl ring caused on average a 27-fold reduction of potency relative to **5q**, while the *para*-methyl compound **5t** was almost as active as **5q**. The replacement of the *para*-methyl with a *para*-methoxy (**5u**), as noted above, was highly detrimental to activity, resulting, on average, in an 83-fold reduction of potency. The compound with a *meta*-methoxy group (**5v**) was similarly inactive.

As noted above, ERG's are not indispensable on the B-ring, as shown by the activity of derivatives **5w–y**. In fact, in the para-position EWG's resulted in compounds (**5w–y**) with substantially more cytostatic activity than was observed with the *para*-methoxy group of compound **5j**.

To investigate whether the antiproliferative activities of this novel series of 4-aminothiazole derivatives involved an interaction with tubulin, a selected series of compounds (**5a**, **5f**, **5l**, **5n**, **5p–q**, **5t**, and **5w**) were evaluated for their in vitro inhibition of tubulin polymerization and for their inhibitory effects on the binding of [³H]colchicine to tubulin (Table 2).

Table 2. Inhibition of Tubulin Polymerization and Colchicine Binding by Compounds **4a**, **5l**, **5n**, **5p–q**, **5t**, **5w**, and CA-4

compd	tubulin assembly ^a IC ₅₀ ± SD (μM)	colchicine binding ^b % ± SD
5a	8.0 ± 0.7	35 ± 2
5f	3.6 ± 0.4	43 ± 2
5l	1.4 ± 0.2	84 ± 2
5n	1.4 ± 0.2	77 ± 4
5p	2.8 ± 0.3	63 ± 0.2
5q	2.5 ± 0.3	75 ± 2
5t	0.72 ± 0.01	87 ± 1
5w	1.1 ± 0.1	89 ± 2
4a	4.0 ± 0.4	58 ± 3
CA-4 (1)	1.4 ± 0.1	87 ± 3

^aInhibition of tubulin polymerization. Tubulin was at 10 μM. ^bInhibition of [³H]colchicine binding. Tubulin, colchicine, and tested compound were at 1, 5, and 1 μM, respectively.

For comparison, CA-4 and **4a** were examined in contemporaneous experiments. In the assembly assay, compound **5t** was found to be the most active (IC₅₀, 0.72 μM) and it was 2- and 5-times more potent than CA-4 and **4a** (IC₅₀'s of 1.4 and 4.0 μM, respectively). Derivatives **5l**, **5n**, and **5w** had activity comparable to that of CA-4, while **5p** and **5q** were about half as potent as CA-4. Unexpectedly, derivatives **5a** and **5f** were 5- and 10-fold less active than **5t** as inhibitors of tubulin assembly although they were 2 orders of magnitude less potent in their effects on cell growth. The reduced antiproliferative activities of **5a** and **5f** may result from poor permeability into cells, poor solubility in the tissue culture medium, or any other mechanism limiting the accessibility of these molecules to cellular tubulin. Alternatively, these molecules may be exerting their effect by a different, as yet uncovered, mechanism of action.




Figure 1. Proposed binding mode of **5t** in the colchicine site. DAMA-colchicine in red.

For these eight compounds, **4a** and CA-4, the order of activity as inhibitors of tubulin assembly was **5t** > **5w** > CA-4 = **5l** = **5n** > **5q** > **5p** > **5f** > **4a** ≫ **5a**. The potent activity of derivatives **5l**, **5n**, and **5w** showed that the 3',4',5'-trimethoxybenzoyl group was not necessary for inhibiting tubulin assembly.

In the colchicine binding studies, derivatives **5l**, **5t**, and **5w** were as potent as CA-4, which in these experiments inhibited colchicine binding by 87%. In general, inhibition of [³H]colchicine binding to tubulin correlated more closely with antiproliferative activity than inhibition of tubulin assembly.

The effects of compounds **5l**, **5n**, **5p–q**, **5t**, and **5w** on the cell cycle were examined by flow cytometry after staining the cells with propidium iodide. HeLa cells were exposed for 24 h to different concentrations of the compounds. All tested compounds (see Figure 1 in the Supporting Information) caused an evident and rapid increase of cells in the G2-M phase, and this was already significant for all compounds at a concentration of 30 nM. A concomitant decrease of cells in the G1 and S phases was also observed. All the compounds also caused the appearance of a hypodiploid peak (sub-G1), indicative of apoptosis (see Figure 2 in the Supporting Information). Compared with the sub-G1 area (8.9%) in control cells, all compounds (except **5l**) showed a significant increase in apoptotic cells in a concentration-dependent manner (see Figure 3 in the Supporting Information).

We also performed a series of molecular docking simulations in the colchicine site of tubulin with the most active compound **5t**.¹¹ The proposed binding of this compound is shown in Figure 1, and it is possible to see how the trimethoxyphenyl moiety is placed in proximity of Cys241 (residue numbering based on the crystal structure used). Furthermore,

binding is stabilized by the presence of three hydrogen bonds between the thiazole core and Thr179, Ser178, and Thr353. These residues (Cys241, Thr179, and Ser178) were also found to be involved in the binding of other tubulin binding agents.¹² Finally, the aromatic ring in position 2 of the thiazole is on the edge of the binding pocket.

In conclusion, we have discovered a new class of structurally simple synthetic inhibitors of tubulin polymerization based on a 2-anilino-4-amino-5-arylthiazole molecular skeleton. With the exception of 3',4',5'-trimethoxybenzoyl derivatives **5u–v**, we found that ERG's on the A-phenyl ring enhanced antiproliferative activity, while EWG's reduced antiproliferative activity. By comparing the effects of ERG's and EWG's on the B-phenyl ring, compounds (i.e., **5j**, **5w**, **5x**, and **5y**) with substituents with opposite electronic effects showed similar potency. We also showed by flow cytometry that selected compounds had cellular effects typical for microtubule-interacting agents, causing accumulation of apoptotic cells and cells in the G2/M phase of the cell cycle. The preparation of these compounds was carried out via an efficient procedure, and they constitute an interesting class of potent antitubulin agents which will be further evaluated as potential anticancer agents.

Experimental Section

General Procedure for the Synthesis of Compounds 5a–y. Sodium (188 mg, 8.2 mmol) was carefully dissolved in MeOH (10 mL) at ambient temperature. The resultant solution was added dropwise, over 10 min, to a mixture of cyanamide (345 mg, 8.2 mmol) and arylisothiocyanate (8.2 mmol, 1 equiv) dissolved in MeOH (5 mL), and cooled with an ice-bath. The appropriate phenacyl bromide (8.2 mmol, 1 equiv) was added in

small portions, and the resulting mixture was stirred overnight at ambient temperature. The mixture was diluted with water (10 mL) and extracted with dichloromethane (3×15 mL). The organic phase was washed with brine (10 mL), dried over Na_2SO_4 , and evaporated. The residue was purified by silica gel column chromatography or crystallized from ethyl ether or petroleum ether.

Acknowledgment. We wish to thank Alberto Casolari for technical assistance.

Supporting Information Available: Detailed biological protocols, molecular modeling procedure, and spectroscopic data for compounds **5a–y**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- (1) Amos, L. A. Microtubule structure and its stabilisation. *Org. Biomol. Chem.* **2004**, *2*, 2153–2160.
- (2) Mahindroo, N.; Liou, J. P.; Chang, J. Y.; Hsieh, H. P. Antitubulin agents for the treatment of cancer. A medicinal chemistry update. *Exp. Opin. Ther. Pat.* **2006**, *16*, 647–691.
- (3) Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. *Experientia* **1989**, *45*, 209–211.
- (4) Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. *Biochemistry* **1989**, *28*, 6984–6991.
- (5) Pettit, G. R.; Toki, B.; Herald, D. L.; Verdier-Pinard, P.; Boyd, M. R.; Hamel, E.; Pettit, R. K. Antineoplastic agents. 379. Synthesis of phenstatin phosphate. *J. Med. Chem.* **1998**, *41*, 1688–1695.
- (6) Liou, J. P.; Chang, C. W.; Song, J. W.; Yang, Y. N.; Yeh, C. F.; Tseng, H. Y.; Lo, Y. K.; Chang, Y. L.; Chang, C. M.; Hsieh, H. P. Synthesis and structure–activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. *J. Med. Chem.* **2002**, *45*, 2556–2572.
- (7) Romagnoli, R.; Baraldi, P. G.; Remusat, V.; Carrion, M. D.; Lopez Cara, C.; Preti, D.; Fruttarolo, F.; Pavani, M. G.; Tabrizi, M. A.; Tolomeo, M.; Grimaudo, S.; Balzarini, J.; Jordan, M. A.; Hamel, E. Synthesis and biological evaluation of 2-(3',4',5'-trimethoxybenzoyl)-3-amino 5-aryl thiophenes as a new class of tubulin inhibitors. *J. Med. Chem.* **2006**, *49*, 6425–6428.
- (8) Mahboobi, S.; Sellemer, A.; Hoche, H.; Eichhorn, E.; Bar, T.; Schmidt, M.; Maier, T.; Stadlweiser, J. F.; Beckers, T. L. [4-(Imidazol-1-yl)thiazol-2-yl]phenylamines. A novel class of highly potent colchicine site binding tubulin inhibitors: synthesis and cytotoxic activity on selected human cancer cell lines. *J. Med. Chem.* **2006**, *49*, 5769–5776.
- (9) Only one compound of this series (**5e**) was reported in literature and showed an IC_{50} average value of $0.35 \mu\text{M}$ against different cancer cell lines. Sengupta, S.; Smitha, S. L.; Thomas, N. E.; Santhoshkumar, T. R.; Devi, K. C.; Sreejalekshmi, K. G.; Rajasekharan, K. N. 4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1): a cytotoxic agent towards cancer cells and a probe for tubulin–microtubule system. *Br. J. Pharmacol.* **2005**, *145*, 1076–1083.
- (10) Gewald, K.; Blauschmidt, P.; Mayer, P. 4-Amino-thiazole. *J. Prakt. Chem.* **1967**, *35*, 97–104.
- (11) Ravelli, R. B. G.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. *Nature* **2004**, *428*, 198–202.
- (12) De Martino, G.; Edler, M. C.; La Regina, G.; Coluccia, A.; Barbera, M. C.; Barrow, D.; Nicholson, R. I.; Chiosis, G.; Brancale, A.; Hamel, E.; Artico, M.; Silvestri, R. Arylthioindoles, potent inhibitors of tubulin polymerization. 2. Structure–activity relationships and molecular modeling studies. *J. Med. Chem.* **2006**, *49*, 947–954.